Detailed Findings
The market for GLP-1 is here to stay, but a question mark remains over the risks attached
Respondents are clear in their assertion that weight loss drugs are going to continue to be a meaningful market for some time. 47% of respondents said that it will be very large and with long-term sustainability, up from a more unsure 33% last year. This conviction was shared across Institutional Investors, Private Equity and Healthcare Corporates.
However, as with last year, 35% of participants are mindful that amidst all the excitement, there are substantial risks that could deflate the market. As we learn more about the drugs, the number of respondents who consider there to be too little information available to make up their minds has reduced – down almost half from 32% in 2023 to 18% in 2024.
0%
47% say the GLP-1 market is very large with long-term sustainability.
Jefferies Financial Group Inc. is the largest independent, global, full-service investment banking and capital markets firm headquartered in the United States. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. www.jefferies.com
IMPORTANT: You must read the following before reading, accessing or making any other use of this publication. In accessing this publication, you agree to be bound by the following terms and conditions. This document is being furnished for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase any security or other financial instrument or product. It is not intended to form the basis of any investment decision. Jefferies International Limited and its affiliates (together “Jefferies”) makes no representation as to the accuracy or completeness of the information contained herein or any other information, whether written or oral, made available. Jefferies disclaims all and any liability whatsoever, whether arising in tort, contract or otherwise, for the contents of this publication. You acknowledge that Jefferies does not owe you or any other person or entity, any fiduciary or similar duty as a result of the publication of this report, and Jefferies is not providing any advice, including with respect to legal, tax, accounting, investment or regulatory matters, in any jurisdiction.
